Skip to main content
Smart Investors Daily
XT

NASDAQ · XTNT

Xtant Medical Holdings, Inc.

Healthcare · Medical - Devices

$0.21

Down-$0.01 (-2.82%)

Updated Nov 22, 2026, 3:17 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
97.85M
P/E ratio
-21.38
Dividend yield
0.00%
52-week range
$0.17 – $0.71
Volume
257.33K
Avg. volume
257.75K

Price performance · XTNT

XTNT price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

XTNT closed at $0.21 after 20 trading sessions, down 23.66% for the selected period.

Last close
$0.21
Period change
-23.66%
Period low
$0.21
Period high
$0.30
Daily close
View OHLC price history
XTNT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$0.25$0.25$0.20$0.21257.33K
Nov 19, 2026$0.2058$0.2194$0.2001$0.2161139.85K
Nov 18, 2026$0.209$0.2164$0.1996$0.2058318.65K
Nov 17, 2026$0.205$0.2298$0.20$0.2052355.52K
Nov 16, 2026$0.26$0.2611$0.17$0.20981.35M
Nov 13, 2026$0.3061$0.3066$0.26$0.2717181.75K
Nov 12, 2026$0.2773$0.2841$0.2725$0.2753144.08K
Nov 11, 2026$0.2759$0.2882$0.2726$0.2779202.43K
Nov 10, 2026$0.295$0.295$0.2725$0.2749662.83K
Nov 9, 2026$0.299$0.299$0.2759$0.279121.95K
Nov 6, 2026$0.2931$0.3072$0.2757$0.289462.9K
Nov 5, 2026$0.3068$0.3115$0.2841$0.30292.01K
Nov 4, 2026$0.2769$0.32$0.2769$0.296190.61K
Nov 3, 2026$0.2756$0.29$0.2756$0.27868.88K
Nov 2, 2026$0.33$0.33$0.2783$0.2784264.95K
Oct 30, 2026$0.281$0.299$0.2802$0.280244.52K
Oct 29, 2026$0.2966$0.2998$0.2844$0.290438.46K
Oct 28, 2026$0.2762$0.2937$0.2753$0.28671.6K
Oct 27, 2026$0.2855$0.2889$0.2752$0.280887.39K
Oct 26, 2026$0.282$0.296$0.2725$0.2751108.63K

Latest XTNT news

The latest Smart Investors Daily articles mentioning XTNT.

XTNT research

Overview

Company profile and research snapshot.

Company profile

Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
XTNT recent ratings
DateFirmRatingTarget
Sep 2, 2026LUCID CAPITAL MARKETSBuy—
May 13, 2026BTIGBuy—
Mar 31, 2026BTIGBuy—
Nov 11, 2025BTIGBuy—
May 16, 2024BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.